HOME THERAPY AREAS Avacopan as first-line treatment in antineutrophil cytoplasmic antibody-associated vasculitis: A steroid-sparing option 30 June 2022 Nephrology and Rare Diseases ANCA-associated vasculitis First study with avacopan in a real-life setting for patients with de novo or relapsing ANCA-associated vasculitis (AAV) View article THERE IS MORE HERE Specialist information is located in this area. In order to be able to see this, you must verify yourself as a healthcare professional. ?